{"schema_version":"1","generated_at":"2026-11-02T02:24:37.861Z","data_as_of":null,"url":"https://www.findmykol.com/kol/carolyn-muller","json_url":"https://www.findmykol.com/kol/carolyn-muller/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"carolyn-muller","name":"Carolyn Muller","credential":"MD","specialty":"Gynecologic Oncology","specialty_raw":"Gynecologic Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of New Mexico","institution_url":"https://www.findmykol.com/institution/university-of-new-mexico","city":"Albuquerque","state":"NM","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1598772550","openalex":"A5034429208"},"summary":"Carolyn Muller is an Oncology physician affiliated with University of New Mexico. OpenAlex indexes 17 publications with 498 citations (h-index 5); ClinicalTrials.gov lists 4 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":17,"cited_by_count":498,"h_index":5,"latest_activity_year":2026,"source":"works"},"trials":{"count":4,"shown":3,"withheld":1,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT07436793","title":"Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"New Mexico Cancer Research Alliance","source_url":"https://clinicaltrials.gov/study/NCT07436793","trial_url":"https://www.findmykol.com/trial/NCT07436793"},{"nct":"NCT02470299","title":"Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients","phase":"NA","status":"COMPLETED","role":"Overall official","sponsor":"New Mexico Cancer Research Alliance","source_url":"https://clinicaltrials.gov/study/NCT02470299","trial_url":"https://www.findmykol.com/trial/NCT02470299"},{"nct":"NCT01670799","title":"Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer","phase":"EARLY_PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"New Mexico Cancer Research Alliance","source_url":"https://clinicaltrials.gov/study/NCT01670799","trial_url":"https://www.findmykol.com/trial/NCT01670799"}],"source":"trials"},"payments":{"company_count":6,"program_years":{"first":2021,"last":null},"rows_total":7,"shown":3,"withheld":4,"rows":[{"payer":"Eli Lilly and Company","program_year":2025,"amount_usd":957,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598772550"},{"payer":"GlaxoSmithKline, LLC.","program_year":2023,"amount_usd":4154.21,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598772550"},{"payer":"Seagen Inc.","program_year":2023,"amount_usd":1220,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598772550"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1598772550","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Sensory organs","share_pct":100,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":100,"drugs":[{"name":"Dexamethasone","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":2014,"last":2026},"rows_total":15,"shown":3,"withheld":12,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"UG1CA189856","title":"The NCI Community Oncology Research Program: The New Mexico NCORP","fiscal_year":2026,"amount_usd":"1397304","organization":"UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR","source_url":"https://reporter.nih.gov/quickSearch/UG1CA189856"},{"project":"UG1CA189856","title":"The NCI Community Oncology Research Program: The New Mexico NCORP","fiscal_year":2025,"amount_usd":"1589898","organization":"UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR","source_url":"https://reporter.nih.gov/quickSearch/UG1CA189856"},{"project":"P30CA118100","title":"Clinical Protocol and Data Management","fiscal_year":2025,"amount_usd":"175491","organization":"UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR","source_url":"https://reporter.nih.gov/quickSearch/P30CA118100"}],"source":"grants"},"publications":{"total":17,"shown":5,"withheld":12,"matched_by":"OpenAlex author record","recent":[{"title":"Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5503","status":"verified"},{"title":"BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers","year":2026,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2026.01.174","status":"verified"},{"title":"A PHASE 2 STUDY OF AVUTOMETINIB (VS-6766; DUAL RAF/MEK INHIBITOR) PLUS DEFACTINIB (FAK INHIBITOR) IN RECURRENT GYNECOLOGICAL CANCERS (DURAFAK)","year":2025,"journal":"International Journal of Gynecological Cancer","source_url":"https://doi.org/10.1016/j.ijgc.2025.102613","status":"verified"},{"title":"2095MO Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)","year":2025,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2025.08.2717","status":"verified"},{"title":"1472TiP Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial","year":2024,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2024.08.1538","status":"verified"}],"source":"works"},"contact":{"address_1":"1201 CAMINO DE SALUD NE","address_2":"MSC 07 4025","city":"Albuquerque","state":"NM","zip":"871310001","phone":"505-925-0460","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1598772550","source":"identity"},"similar":[{"name":"Corey Ford","slug":"corey-ford","institution":"University of New Mexico","specialty":"Neurology","url":"https://www.findmykol.com/kol/corey-ford","json_url":"https://www.findmykol.com/kol/corey-ford/profile.json"},{"name":"Denise Lin","slug":"denise-lin","institution":"University of New Mexico","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/denise-lin","json_url":"https://www.findmykol.com/kol/denise-lin/profile.json"},{"name":"Andrew Matsumoto","slug":"andrew-matsumoto","institution":"University of New Mexico","specialty":"Dermatology","url":"https://www.findmykol.com/kol/andrew-matsumoto","json_url":"https://www.findmykol.com/kol/andrew-matsumoto/profile.json"},{"name":"Mauricio Tohen","slug":"mauricio-tohen","institution":"University of New Mexico","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/mauricio-tohen","json_url":"https://www.findmykol.com/kol/mauricio-tohen/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":1,"payments":4,"funding":12,"publications":12}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-09-26","provider_certified":"2024-09-26","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}